Vol. 4 No. 12 (2024)
Reimbursement Reviews

Atogepant (Qulipta)

decorative image of the issue cover

Published December 13, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses atogepant (Qulipta), tablets, 10 mg, 30 mg, and 60 mg, oral.
  • Indication: For the prevention of migraine in adults who have at least 4 migraine days per month.